Senti Biosciences stockholders elect three Class I directors and ratify KPMG at 2023 annual meeting

Senti Biosciences, Inc.

Timothy Lu, M.D., Ph.D. elected with 32.3M votes for; Edward Mathers elected with 22.5M for; Omid Farokhzad, M.D. elected with 26.2M for.
KPMG LLP ratified as independent auditor for fiscal 2023 with 34.4M votes for, 60,890 against, 54,266 abstain.
Meeting held June 16, 2023; 34.5M shares represented (78.0% of outstanding).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Senti Biosciences, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-16

Exact text from the filing

2. Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain 34,350,453 60,890 54,266

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Senti Biosciences, Inc. shareholders approved Election of three Class I directors: Timothy Lu, M.D., Ph.D., Edward Mathers, and Omid Farokhzad, M.D. at the 2023-06-16 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-16

Exact text from the filing

1. Election of directors: Name For Withheld Broker Non-Votes Timothy Lu, M.D., Ph.D. 32,295,728 81,697 2,088,184 Edward Mathers 22,511,863 9,865,562 2,088,184 Omid Farokhzad, M.D. 26,184,748 6,192,677 2,088,184

View on SEC.gov

72 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.